Citadel Advisors’s Celyad Oncology SA American Depositary Shares CYAD Stock Holding History

Citadel Advisors’s Portfolio CYAD Stock Details CYAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-16,285	Closed	-$15.3K	–	15694
2023 Q1	$15.3K	Sell	16,285 -13,534	-45%	-$15.3K	﹤0.01%	13262
2022 Q4	$14K	Buy	29,819 +13,165	+79%	+$13.3K	﹤0.01%	13412
2022 Q3	$22K	Buy	+16,654	New	+$30.6K	﹤0.01%	12047
2022 Q2	–	Sell	-14,598	Closed	-$35K	–	14600
2022 Q1	$35K	Buy	+14,598	New	+$44.7K	﹤0.01%	13026

Other funds holding CYAD

BBA

Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

Citadel Advisors's CYAD Position: Q2 2023 in Review

Citadel Advisors sold out of Celyad Oncology SA American Depositary Shares (CYAD) in Q2 2023, closing a stake of 16,285 shares — an estimated $15.3K sold.

Citadel Advisors first reported a position in CYAD in Q1 2022 and held it in 4 quarters. The position peaked at $35K in Q1 2022. 2 funds tracked by Wall St. Rank hold CYAD as of Q2 2023.

Citadel Advisors reported no remaining Celyad Oncology SA American Depositary Shares position as of Q2 2023 after selling out during the quarter.
Citadel Advisors sold 16,285 Celyad Oncology SA American Depositary Shares shares in Q2 2023, an estimated $15.3K.
Citadel Advisors first reported a position in Celyad Oncology SA American Depositary Shares in Q1 2022 and held it in 4 quarters.
Citadel Advisors's Celyad Oncology SA American Depositary Shares position peaked at $35K in Q1 2022.
2 funds tracked by Wall St. Rank held Celyad Oncology SA American Depositary Shares as of Q2 2023.

Based on Citadel Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.